John Sourbeer
Stock Analyst at UBS
(0.73)
# 4,155
Out of 5,182 analysts
44
Total ratings
42.86%
Success rate
-17.79%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $10.17 | +22.91% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $125.44 | -4.34% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $309.70 | +14.63% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $37.97 | +25.41% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $106.34 | +125.69% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $16.24 | +44.70% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $11.24 | +300.36% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.57 | +27.39% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $393.42 | +22.01% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $36.22 | +181.61% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $21.42 | +133.43% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $92.48 | +38.41% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $10.17
Upside: +22.91%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $125.44
Upside: -4.34%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $309.70
Upside: +14.63%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $37.97
Upside: +25.41%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $106.34
Upside: +125.69%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $16.24
Upside: +44.70%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $11.24
Upside: +300.36%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.57
Upside: +27.39%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $393.42
Upside: +22.01%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $36.22
Upside: +181.61%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $21.42
Upside: +133.43%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $92.48
Upside: +38.41%